Skip to main content

Botox Disease Interactions

There are 3 disease interactions with Botox (onabotulinumtoxinA).

Major

Botulinum toxin products (applies to Botox) dysphagia/respiratory/neuromuscular disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment, Myasthenia Gravis

Treatment with botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, daxibotulinumtoxinA and others can result in swallowing and breathing difficulties and in general increased neuromuscular compromise. Deaths due to severe dysphagia or respiratory failure have been reported after treatment with botulinum toxin. Care should be exercised with using these products in patients with pre- existing swallowing or respiratory disorders or peripheral motor neuropathic diseases or neuromuscular disorders (e.g., myasthenia gravis, amyotrophic lateral sclerosis), as they may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia and respiratory compromise. Patients treated with botulinum toxin may require immediate medical attention should they develop these complications. Caution is advised.

References

  1. "Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc
  2. "Product Information. Botox (onabotulinumtoxinA)." Allergan Inc
  3. "Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals (2022):
  4. "Product Information. Daxxify (daxibotulinumtoxinA)." Revance Therapeutics, Inc. (2022):
View all 4 references
Major

Botulinum toxin products (applies to Botox) infection

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Botulinum toxin products, including abobotulinumtoxinA, incobotulinumtoxinA, onabotulinumtoxinA, and others should not be used in the presence of infection at the proposed injection site(s) as it could lead to severe local or disseminated infection(s).

References

  1. "Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc
  2. "Product Information. Botox (onabotulinumtoxinA)." Allergan Inc
  3. "Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals (2022):
  4. "Product Information. Daxxify (daxibotulinumtoxinA)." Revance Therapeutics, Inc. (2022):
View all 4 references
Major

OnabotulinumtoxinA (applies to Botox) UTI

Major Potential Hazard, Moderate plausibility. Applicable conditions: Urinary Tract Infection, Urinary Retention

Botox (brand of onabotulinumtoxinA), a botulinum toxin product for the treatment of overactive bladder or detrusor overactivity associated with a neurologic condition should not be used in patients who have a urinary tract infection, in patients with urinary retention and in patients with post-void residual urine volume >200 mL, who are not routinely performing clean intermittent self-catheterization.

References

  1. "Product Information. Botox (onabotulinumtoxinA)." Allergan Inc

Botox drug interactions

There are 114 drug interactions with Botox (onabotulinumtoxinA).


Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.